Previous studies have reported that gut microbiota affects the efficacy of immunotherapy in EGFR- NSCLC [20, 21, 31, 32], including Akkermansia muciniphila, Bifidobacterium bifidum, and Bifidobacterium breve. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.